BCTX - Briacell down 8% despite positive data on breast cancer candidate BRIA-IMT

Shares of BriaCell (BCTX -9.4%) are down today despite presenting mid-stage data on its breast cancer candidate BRIA-IMT in combination with immune checkpoint inhibitors. Phase 1/2a results presented at the San Antonio Breast Cancer Symposium showed that disease control was 25% and 30% in two monotherapy studies and 33% in a combination study. In a cohort of patients that had nine prior regimens and received combination therapy, overall survival was 12 months. That compares to 7.2-9.8 months in patients who received leading treatment with two prior regimens. BriaCell said that the data indicates that combining BRIA-IMT with an immune checkpoint inhibitor provides an additive or synergistic effect. The company received authorization for a share buyback in September.

For further details see:

Briacell down 8% despite positive data on breast cancer candidate BRIA-IMT